Sommario
Il trattamento farmacologico dell’osteoporosi si basa sui farmaci che inibiscono la distruzione ossea oppure su quelli che stimolano la formazione scheletrica. L’abaloparatide è un farmaco anabolizzante, costituito da un analogo sintetico del PTHrP. Gli studi clinici fino ad ora condotti hanno evidenziato la capacità di questa sostanza di ridurre l’incidenza, rispetto al placebo, delle fratture vertebrali, non vertebrali, delle fratture cliniche e delle principali fratture osteoporotiche. Questo farmaco si aggiunge quindi all’armamentario terapeutico del gruppo dei farmaci anabolizzanti fino ad ora rappresentato solo dal PTH 1–34.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
Minisola S, Cipriani C, Occhiuto M, Pepe J (2017) New anabolic therapies for osteoporosis. Int Emerg Med 12(7):915–921
Kanis JA, Cooper C, Rizzoli R et al., the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28(7):2023–2034
Minisola S, Pepe J, Piemonte S, Cipriani C (2015) The diagnosis and management of hypercalcaemia. BMJ 350:h2723
Hattersley G, Dean T, Corbin BA et al. (2016) Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling. Endocrinology 157(1):141–149
Chew CK, Clarke BL (2017) Abaloparatide: recombinant human PTHrP (1–34) anabolic therapy for osteoporosis. Maturitas 97:53–60
Leder BZ, O’Dea LS, Zanchetta JR et al. (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100(2):697–706
Miller PD, Hattersley G, Riis BJ et al., the ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722–733
Cosman F, Hattersley G, Hu MY et al. (2017) Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res 32(1):17–23
McCloskey EV, Johansson H, Oden A et al. (2017) The effect of abaloparatide-sc on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res 32(8):1625–1631
Moreira CA, Fitzpatrick LA, Wang Y, Recker RR (2017) Effects of abaloparatide-sc (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone 97:314–319
Cosman F, Miller PD, Williams GC et al. (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc 92(2):200–210
Mazziotti G, Formenti AM, Adler RA et al. (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54(3):603–611
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitto di interesse
Gli autori Salvatore Minisola, Chiara Sonato, Veronica Cecchetti, Evelina Vigna, Vittoria Danese e Luciano Colangelo dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Additional information
Proposto da Salvatore Minisola.
Materiale elettronico supplementare
Rights and permissions
About this article
Cite this article
Minisola, S., Sonato, C., Cecchetti, V. et al. Abaloparatide. L'Endocrinologo 19, 75–78 (2018). https://doi.org/10.1007/s40619-018-0417-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-018-0417-4